Acutaas Chemicals Limited (formerly known as Ami Organics Limited) is one of the leading research and development-driven manufacturers of specialty chemicals. The company manufactures different types of Advanced Pharmaceutical Intermediates and Active Pharmaceutical Ingredients (API) for New Chemical Entities, and materials for agrochemicals and fine chemicals. The Board of Ami Organics at its meeting held on April 16, 2025, approved the change in the name of the Company from 'Ami Organics' to 'Acutaas Chemicals', and the consequential alteration of the Memorandum of Association and Articles of Association to give effect to the same.
The company operates as a comprehensive specialty chemicals manufacturer with a focus on pharmaceutical intermediates, serving both domestic and international markets. The Company is focused on the development and manufacturing of advanced pharmaceutical intermediates (Pharma Intermediates), New Chemical Entities (NCE), and other specialty chemicals for pharmaceuticals, agrochemicals, dyes, polymers, personal care, animal food, and other Industries.
It manufactures pharma intermediates for certain active pharmaceutical ingredient (APIs), including dolutegravir, trazodone, entacapone, nintedanib, and rivaroxaban. The pharma intermediates cater to several therapeutic areas, including anti-retroviral, anti-inflammatory, anti-psychotic, anti-cancer, anti-Parkinson, anti-depressant, and anti-coagulant. The Company has developed and commercialized over 520 plus products, including specialty chemicals, Pharma Intermediates for APIs across 23 key therapeutic areas since inception, and NCE across select high-growth high margin chronic therapeutic areas.
The company's manufacturing capabilities are diverse, with the 450 pharma intermediate products it manufactures used to make APIs and NCEs, with applications in high-growth therapeutic areas such as antiretroviral, anti-inflammatory, antipsychotic, anticancer, anti-Parkinson, antidepressant, and anticoagulant. This extensive product portfolio positions Acutaas as a significant player in the specialty chemicals sector, particularly in pharmaceutical intermediates.
Acutaas Chemicals has a market capitalization of ₹9,187 Crore (up 57.3% in 1 year) with revenue of ₹1,007 Crore and profit of ₹160 Crore. Acutaas Chemicals Ltd has a market capitalization of ₹9,554 Crore as on June 30, 2025. The company achieved a significant milestone by proudly surpassing ₹1,000 Crore in revenue for FY25, marking a remarkable achievement.
For the financial year ended March 2025, the company demonstrated strong performance.
- Net profit rose 271.08% to ₹158.71 Crore in the year ended March 2025, as against ₹42.77 Crore during the previous year ended March 2024.
- Sales rose 40.34% to ₹1,006.88 Crore in the year ended March 2025, as against ₹717.47 Crore during the previous year ended March 2024.
The Q4 FY25 results were particularly impressive:
- Revenue from operations jumping 37.13% year on year to ₹308.48 Crore during the quarter ended March 31, 2025.
- Profit before tax (PBT) soared 122.66% to ₹82.83 Crore in Q4 FY25 as compared with ₹37.20 Crore in Q4 FY24.
- EBITDA stood at ₹85 Crore, registering the growth of 96.8% as compared with ₹432 Crore in Q4 FY24.
- EBITDA margin was at 27.5% in Q4 FY25 as against 19.2% in Q4 FY24.
- Market Cap: ₹9,554 Crore (as of June 30, 2025)
- Revenue FY25: ₹1,007 Crore (up 40.34% YoY)
- Net Profit FY25: ₹159 Crore (up 271.08% YoY)
- Q4 FY25 Revenue: ₹308.48 Crore (up 37.13% YoY)
- Q4 FY25 Net Profit: ₹62.48 Crore (up 148.43% YoY)
As of the last reported quarter for Acutaas Chemicals Ltd., Promoter held 36%, the FII held 16.5%, DII held 18.3%, and the public held 29.2% of the total shares. Foreign institutional investors increased their stake to 16.48%, while retail investors hold 29.22%. Ace investor Ashish Kacholia owns 1.7% as of March 2025.
The company is positioned for continued growth with strategic investments and expansion plans. Ami Organics has signed an MOU with the Gujarat government for a ₹3 billion investment in an electrolyte manufacturing facility. The plant, costing ₹1.77 billion, is expected to be completed by H1 FY26. The company has signed an MoU with the Gujarat government for ₹530 Crore in investments, including a dedicated battery chemicals plant.
Management remains optimistic about future growth prospects. Looking ahead to FY26, the company anticipates robust growth across all business segments, driving its confidence in achieving 25% revenue growth. With zero debt and a commitment to maintaining a strong financial position, the company is investing INR 200 Crore in capital expenditures to enhance production capabilities.
The company has made significant strides in sustainability. Ami Organics announced the full commissioning of its 10.8 MW DC solar power plant. The solar facility, located at Pratapnagar, Nandod, Narmada District, Gujarat, India, comprises two captive solar plants, each with a capacity of 5.4 MW. This initiative strengthens the company's environmental responsibility while enhancing operational efficiency.
Acutaas Chemicals Stock Price Today (NSE: ACUTAAS, BSE: 543349) trades on both major Indian exchanges. The shares are listed on BSE Ltd. and NSE since September 14, 2021. The company issued a bonus share of 2:1 to existing shareholders on March 31, 2021, and also came out with an IPO in September 2021, mopping up ₹570 Crore.
83.33% of analysts recommend a 'BUY' rating for Acutaas Chemicals Ltd. The average target price is ₹1357.5 according to 6 analyst ratings. The mean consensus is BUY with 6 analysts covering the stock. The average target price is 1,357.50 INR with a spread of +18.93%.
Acutaas Chemicals Limited represents a compelling investment opportunity in the Indian specialty chemicals sector, with its strong fundamentals, diversified product portfolio, robust financial performance, and strategic growth initiatives positioning it well for future expansion in both domestic and international markets.
